A phase III double blind, clinical endpoint study of REMUNE to evaluate HIV disease progression, AIDS or death.
Phase of Trial: Phase III
Latest Information Update: 23 Feb 2017
At a glance
- Drugs GP120-depleted HIV-1 vaccine (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 23 Feb 2017 Based upon a recommendation from the Data Safety Management Board (DSMB), this study 806 was terminated in May 1999.
- 23 Feb 2017 New trial record
- 30 Dec 2016 Results published in the Immune Response BioPharma Media Release.